Nathan Rice
Stock Analyst at Piper Sandler
(3.12)
# 1,082
Out of 5,182 analysts
63
Total ratings
51.28%
Success rate
12.28%
Average return
Main Sectors:
Stocks Rated by Nathan Rice
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BY Byline Bancorp | Maintains: Overweight | $37 → $40 | $33.44 | +19.62% | 10 | Apr 27, 2026 | |
| BFC Bank First | Maintains: Neutral | $150 → $157 | $149.11 | +5.29% | 11 | Apr 20, 2026 | |
| FMBH First Mid Bancshares | Maintains: Overweight | $49 → $48 | $44.01 | +9.07% | 5 | Nov 3, 2025 | |
| MBIN Merchants Bancorp | Maintains: Overweight | $41 → $42 | $49.63 | -15.37% | 9 | Oct 30, 2025 | |
| CVS CVS Health | Maintains: Buy | $85 → $74 | $81.08 | -8.73% | 2 | May 2, 2024 | |
| NIC Nicolet Bankshares | Assumes: Neutral | $84 | $148.49 | -43.43% | 1 | Jan 10, 2024 | |
| ALGN Align Technology | Downgrades: Sell | $197 | $175.72 | +12.11% | 10 | Dec 11, 2023 | |
| ELAN Elanco Animal Health | Maintains: Sell | $11 → $9 | $22.27 | -59.59% | 1 | Apr 25, 2023 | |
| IDXX IDEXX Laboratories | Upgrades: Buy | $530 → $435 | $568.08 | -23.43% | 4 | Jul 21, 2022 | |
| CI The Cigna Group | Initiates: Neutral | $233 | $285.68 | -18.44% | 5 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $83 | $48.80 | +70.08% | 4 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $15 | $20.90 | -28.23% | 1 | Dec 19, 2019 |
Byline Bancorp
Apr 27, 2026
Maintains: Overweight
Price Target: $37 → $40
Current: $33.44
Upside: +19.62%
Bank First
Apr 20, 2026
Maintains: Neutral
Price Target: $150 → $157
Current: $149.11
Upside: +5.29%
First Mid Bancshares
Nov 3, 2025
Maintains: Overweight
Price Target: $49 → $48
Current: $44.01
Upside: +9.07%
Merchants Bancorp
Oct 30, 2025
Maintains: Overweight
Price Target: $41 → $42
Current: $49.63
Upside: -15.37%
CVS Health
May 2, 2024
Maintains: Buy
Price Target: $85 → $74
Current: $81.08
Upside: -8.73%
Nicolet Bankshares
Jan 10, 2024
Assumes: Neutral
Price Target: $84
Current: $148.49
Upside: -43.43%
Align Technology
Dec 11, 2023
Downgrades: Sell
Price Target: $197
Current: $175.72
Upside: +12.11%
Elanco Animal Health
Apr 25, 2023
Maintains: Sell
Price Target: $11 → $9
Current: $22.27
Upside: -59.59%
IDEXX Laboratories
Jul 21, 2022
Upgrades: Buy
Price Target: $530 → $435
Current: $568.08
Upside: -23.43%
The Cigna Group
Dec 14, 2021
Initiates: Neutral
Price Target: $233
Current: $285.68
Upside: -18.44%
Dec 14, 2021
Initiates: Neutral
Price Target: $83
Current: $48.80
Upside: +70.08%
Dec 19, 2019
Initiates: Overweight
Price Target: $15
Current: $20.90
Upside: -28.23%